William M. Sikov, MD, on the CALGB 40603 Trial
2014 San Antonio Breast Cancer SymposiumWilliam M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, "Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709 (Alliance)."
Related Videos
Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial
Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “...
Ann H. Partridge, MD, MPH, on Patient-Reported Outcomes From the SOFT Trial
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, on abstract S3-09, “...
Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial
Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08,
Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer
Jame Abraham, MD, FACP, of the Cleveland Clinic, offers his thoughts on abstract S1-09, "
Lisa A. Carey, MD, on the TNT Trial
Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discusses abstract S3-01,
